Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The antifibrotic effect of Vildagliptin and Diaminodiphenyl Sulfone in murine schistosomiasis mansoni.

Scientific reports·2025
Same author

To Target or Not to Target <i>Schistosoma mansoni</i> Cyclic Nucleotide Phosphodiesterase 4A?

International journal of molecular sciences·2023
Same author

Vildagliptin alleviates liver fibrosis in NASH diabetic rats via modulation of insulin resistance, oxidative stress, and inflammatory cascades.

Life sciences·2022
Same author

Gut microbiota modulation as a promising therapy with metformin in rats with non-alcoholic steatohepatitis: Role of LPS/TLR4 and autophagy pathways.

European journal of pharmacology·2020
Same author

Cloning and functional complementation of ten Schistosoma mansoni phosphodiesterases expressed in the mammalian host stages.

PLoS neglected tropical diseases·2020
Same author

Deciphering the enzymatic target of a new family of antischistosomal agents bearing a quinazoline scaffold using complementary computational tools.

Journal of enzyme inhibition and medicinal chemistry·2020
Same journal

Why Next-generation mechanistic models Will transform drug discovery: integrating efficacy and safety.

Expert opinion on drug discovery·2026
Same journal

Toward a nuanced framework for the medical development of ibogaine and its analogues and derivatives: implications for psychopharmacology.

Expert opinion on drug discovery·2026
Same journal

From mitochondrial signal to discovery decision: a reserve-demand framework for translational risk assessment.

Expert opinion on drug discovery·2026
Same journal

Advances in 3D cell culture models for alzheimer's disease drug discovery.

Expert opinion on drug discovery·2026
Same journal

Are patient-derived models of amyotrophic lateral sclerosis a game changer for novel drug discovery?

Expert opinion on drug discovery·2026
Same journal

Unfolding prion misfolding and the challenge of identifying effective therapeutics: is there hope on the horizon?

Expert opinion on drug discovery·2026
See all related articles

Related Experiment Video

Updated: May 13, 2026

QTL Mapping and CRISPR/Cas9 Editing to Identify a Drug Resistance Gene in Toxoplasma gondii
11:37

QTL Mapping and CRISPR/Cas9 Editing to Identify a Drug Resistance Gene in Toxoplasma gondii

Published on: June 22, 2017

Praziquantel resistance.

Sanaa S Botros1, James L Bennett

  • 1Theodor Bilharz Research Institute, Warrak El-Hadar, Imbaba, P.O. Box 30, Giza 12411, Egypt sanaabotros@link.net.

Expert Opinion on Drug Discovery
|March 16, 2013
PubMed
Summary
This summary is machine-generated.

Praziquantel (PZQ) resistance in schistosomes is a growing concern, with studies showing reduced drug efficacy. Systematic monitoring and new treatment strategies are crucial for effective schistosomiasis control.

More Related Videos

Determination of Chemical Inhibitor Efficiency against Intracellular Toxoplasma Gondii Growth Using a Luciferase-Based Growth Assay
09:49

Determination of Chemical Inhibitor Efficiency against Intracellular Toxoplasma Gondii Growth Using a Luciferase-Based Growth Assay

Published on: April 29, 2020

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing &#946;-galactosidase
08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

Related Experiment Videos

Last Updated: May 13, 2026

QTL Mapping and CRISPR/Cas9 Editing to Identify a Drug Resistance Gene in Toxoplasma gondii
11:37

QTL Mapping and CRISPR/Cas9 Editing to Identify a Drug Resistance Gene in Toxoplasma gondii

Published on: June 22, 2017

Determination of Chemical Inhibitor Efficiency against Intracellular Toxoplasma Gondii Growth Using a Luciferase-Based Growth Assay
09:49

Determination of Chemical Inhibitor Efficiency against Intracellular Toxoplasma Gondii Growth Using a Luciferase-Based Growth Assay

Published on: April 29, 2020

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing &#946;-galactosidase
08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

Area of Science:

  • Parasitology
  • Drug Resistance Studies
  • Tropical Medicine

Background:

  • Praziquantel (PZQ) is the primary drug for treating schistosomiasis.
  • Reports of treatment failures suggest potential PZQ resistance in schistosomes.
  • In vivo and in vitro studies indicate reduced PZQ efficacy against certain schistosome isolates.

Purpose of the Study:

  • To highlight the emerging issue of praziquantel resistance in schistosomiasis.
  • To emphasize the need for systematic monitoring of PZQ efficacy and parasite susceptibility.
  • To advocate for the development of new treatment strategies and resistance detection methods.

Main Methods:

  • Review of existing literature on PZQ treatment outcomes and resistance.
  • Analysis of in vivo and in vitro studies demonstrating reduced drug efficacy.
  • Discussion of limitations in current diagnostic and monitoring methods for schistosomiasis cure rates.

Main Results:

  • Multiple PZQ doses fail to cure patients in various geographic locations.
  • Experimental studies confirm reduced efficacy of PZQ against resistant schistosome strains.
  • Current cure rate estimations may be inflated due to diagnostic method sensitivities and sampling limitations.

Conclusions:

  • Systematic monitoring of PZQ efficacy, including egg excretion reduction and susceptibility testing, is essential.
  • Investigating field isolates with diminished sensitivity is necessary to understand resistance mechanisms.
  • Developing new drugs, strategies, and rapid resistance tests is crucial for future schistosomiasis control.